医学综述
醫學綜述
의학종술
MEDICAL RECAPITULATE
2015年
12期
2188-2190
,共3页
李玲%马华玲%张文娟(综述)%杨赤兵(审校)
李玲%馬華玲%張文娟(綜述)%楊赤兵(審校)
리령%마화령%장문연(종술)%양적병(심교)
小肠腺癌%致癌因素%辅助化疗%姑息化疗%分子靶向治疗
小腸腺癌%緻癌因素%輔助化療%姑息化療%分子靶嚮治療
소장선암%치암인소%보조화료%고식화료%분자파향치료
Small bowel adenocarcinoma%Risk factor%Adjuvant chemotherapy%Palliative chemotherapy%Molecular targeted therapy
小肠腺癌是较少见的恶性肿瘤,其发病与不健康饮食、基因突变和某些遗传性疾病有关,十二指肠是好发部位。小肠腺癌的5年生存率较低,临床多采用手术切除及术后辅助化疗的治疗方式。术后辅助化疗能改善无瘤生存期,但对总生存期无明显改善;对晚期癌症患者,使用FOLFOX方案(5-氟尿嘧啶、亚叶酸钙和奥沙利铂)疗效较好。血清中基础癌胚抗原和糖类抗原19-9水平是评估预后的主要因素,而分子靶向治疗尚处在探索中。
小腸腺癌是較少見的噁性腫瘤,其髮病與不健康飲食、基因突變和某些遺傳性疾病有關,十二指腸是好髮部位。小腸腺癌的5年生存率較低,臨床多採用手術切除及術後輔助化療的治療方式。術後輔助化療能改善無瘤生存期,但對總生存期無明顯改善;對晚期癌癥患者,使用FOLFOX方案(5-氟尿嘧啶、亞葉痠鈣和奧沙利鉑)療效較好。血清中基礎癌胚抗原和糖類抗原19-9水平是評估預後的主要因素,而分子靶嚮治療尚處在探索中。
소장선암시교소견적악성종류,기발병여불건강음식、기인돌변화모사유전성질병유관,십이지장시호발부위。소장선암적5년생존솔교저,림상다채용수술절제급술후보조화료적치료방식。술후보조화료능개선무류생존기,단대총생존기무명현개선;대만기암증환자,사용FOLFOX방안(5-불뇨밀정、아협산개화오사리박)료효교호。혈청중기출암배항원화당류항원19-9수평시평고예후적주요인소,이분자파향치료상처재탐색중。
Small bowel adenocarcinomas ( SBA ) are relatively rare kinds of malignant tumours. Unhealthy diet,gene mutation and genetic diseases have been associated with increased risk of SBA .Duode-nal is the primary site of SBA.The 5-year survival rate of SBA patients is low.Radical resection and postoper-ative adjuvant chemotherapy is the general clinical treatment for SBA ,althoughf adjuvant chemotherapy after operation can improve the disease-free survival,but has no obvious effect on the overall survival.In patients with advanced cancer,FOLFOX scheme (fluorouracil,leucovorin and oxaliplatin) has better effect.The ser-um levels of carcinoembryonic antigen and carbohydrate antigen 19-9 are the only variables significantly asso-ciated with prognostic assessment.While molecular targeted therapy for SBA has been under exploration.